 My Collegium Pharmaceutical position has been gathering thanks to the ticker trading between my Buy and Sell Targets. The companys Q3 earnings beat has forced me to update my strategy. Collegiums new products from the BDSI acquisition have already helped the company report record revenue. In addition, the companys Xtampza ER will have an improved gross-to-net starting January 1st. 